| Literature DB >> 26501254 |
Abstract
In addition to interacting with functional proteins such as receptors, ion channels, and enzymes, a variety of drugs mechanistically act on membrane lipids to change the physicochemical properties of biomembranes as reported for anesthetic, adrenergic, cholinergic, non-steroidal anti-inflammatory, analgesic, antitumor, antiplatelet, antimicrobial, and antioxidant drugs. As well as these membrane-acting drugs, bioactive plant components, phytochemicals, with amphiphilic or hydrophobic structures, are presumed to interact with biological membranes and biomimetic membranes prepared with phospholipids and cholesterol, resulting in the modification of membrane fluidity, microviscosity, order, elasticity, and permeability with the potencies being consistent with their pharmacological effects. A novel mechanistic point of view of phytochemicals would lead to a better understanding of their bioactivities, an insight into their medicinal benefits, and a strategic implication for discovering drug leads from plants. This article reviews the membrane interactions of different classes of phytochemicals by highlighting their induced changes in membrane property. The phytochemicals to be reviewed include membrane-interactive flavonoids, terpenoids, stilbenoids, capsaicinoids, phloroglucinols, naphthodianthrones, organosulfur compounds, alkaloids, anthraquinonoids, ginsenosides, pentacyclic triterpene acids, and curcuminoids. The membrane interaction's applicability to the discovery of phytochemical drug leads is also discussed while referring to previous screening and isolating studies.Entities:
Keywords: drug lead; membrane fluidity; membrane interaction; molecular mechanism; phytochemical
Mesh:
Substances:
Year: 2015 PMID: 26501254 PMCID: PMC6332185 DOI: 10.3390/molecules201018923
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of membrane-interactive flavonoids.
Figure 2Structures of membrane-interactive terpenoids.
Figure 3Structures of membrane-interactive stilbenoids.
Figure 4Structures of membrane-interactive capsaicinoids.
Figure 5Structures of membrane-interactive phloroglucinols and naphthodianthrones.
Figure 6Structures of membrane-interactive organosulfur compounds.
Figure 7Structures of membrane-interactive alkaloids.
Figure 8Structures of membrane-interactive anthraquinonoids.
Figure 9Structures of membrane-interactive ginsenosides.
Figure 10Structures of membrane-interactive pentacyclic triterpene acids.
Figure 11Structures of membrane-interactive curcuminoids.
Phytochemicals with the membrane interactivity.
| Phytochemicals or Plants | Used Membranes | Experimental Methods | Membrane Effects | References |
|---|---|---|---|---|
| Naringenin; Rutin | SLPC unilamellar vesicles | FA with 6-AS, 12-AS and 16-AP | Decrease the fluidity | [ |
| Apigenin; Luteolin; Kaempferol; Quercetin; Myricetin; Naringenin; Eriodictyol; Taxifolin; Pelargonidin; Cyanidin; Delphinidin; (–)-Epicatechin; (–)-Epigallocatechin; (–)-Epigallocatechin-3-gallate; Phloretin | POPC/POPE/POPS/cholesterol unilamellar vesicles | FP with 2-AS, 6-AS, 9-AS, 12-AS and 16-AP | Decrease the fluidity | [ |
| Kaempferol; Quercetin; Chrysin; Baicalein; Luteolin | DPPC unilamellar vesicles; DPPG unilamellar vesicles | FP with DPH | Decrease the fluidity | [ |
| Galangin; Quercetin; Kaempferol; Chrysin; Baicalein; Fisetin; Luteolin; Apigenin; Myricetin; Morin; Rutin; Isoquercitrin | POPC/POPE/SOPS/cholesterol unilamellar vesicles | FP with 2-AS, 6-AS, 9-AS, 12-AS and 16-AP | Decrease the fluidity | [ |
| Quercetin; (–)-Epigallocatechin-3-gallate | Human U937 monocyte membranes; Jurkat T lymphoblast membranes | FA with TMA-DPH | Decrease the fluidity | [ |
| (–)-Epicatechin; (–)-Epigallocatechin; (–)-Epigallocatechin-3-gallate; (–)-Epicatechin-3-gallate | DPPC liposomes; DOPC liposomes | FP with PNA and ANS | Decrease the fluidity | [ |
| (–)-Epicatechin; (+)-Epicatechin; (–)-Catechin; (+)-Catechin | DPPC liposomes; DOPC liposomes; DOPC/cholesterol liposomes | FP with PNA and ANS | Decrease the fluidity | [ |
| Genistein | SLPC unilamellar vesicles | FA with 6-AS, 12-AS and 16-AP | Decrease the fluidity | [ |
| Puerarin; Ononin; Daidzein; Genistin | DPPC unilamellar vesicles; DPPG unilamellar vesicles | FP with DPH | Increase the fluidity | [ |
| Genistein | Erythrocyte membranes | EPR | Decrease the fluidity | [ |
| Daidzein | Erythrocyte membranes | EPR | Increase the fluidity | [ |
| Geraniol | FA with 2-AS, 6-AS, 9-AS, 12-AS, DPH and TMA-DPH | Increase the fluidity from the membrane surface to the membrane interior | [ | |
| Carvacrol | Langmuir monolayer membranes of bacterial phospholipids | Surface pressure-area (π-A) and surface potential-area (Δψ-A) isotherms | Increase the fluidity | [ |
| Thymol; Eugenol; Carvacrol | DPPC multilamellar vesicles | FA with DPH and TMA-DPH | Increase the fluidity | [ |
| Nerolidol; Menthol; Pulegone; Carvone; (+)-Limonene; α-Terpineol; 1,8-Cineol | Mouse fibroblast membranes; Human erythrocyte membranes | EPR | Increase the fluidity | [ |
| Linalool; 1,8-Cineol; α-Terpineol | Scanning electron microscopy | Alter the permeability and function | [ | |
| Citral | Soybean phospholipid liposomes | FP with DPH | Decrease the fluidity | [ |
| Borneol | DPPC liposomes | Coarse-grained molecular dynamics simulations | Increase the fluidity | [ |
| Resveratrol | DPPC liposomes; POPC liposomes; POPC/cholesterol liposomes | FP with DPH and TMA-DPH | Decrease the fluidity | [ |
| Resveratrol | Lipid bilayer liposomal membranes | NMR spectroscopy | Decrease the fluidity | [ |
| Resveratrol | DPPC unilamellar vesicles | FA with TMA-DPH | Increase the fluidity | [ |
| Resveratrol; Piceatannol | DPPC liposomes; DMPC liposomes | DSC; ESR; Fluorescence spectroscopy | Alter the phospholipid phase transition | [ |
| Capsaicin | Non-neuronal plasma membranes | FP with DPH and TMA-DPH | Increase the fluidity | [ |
| Capsaicin; | Platelet mimetic membranes; Bacterial cell mimetic membranes | FP with PNA, DPH and TMA-DPH | Increase the fluidity at ~50 μM Decrease the fluidity at 100–500 μM | [ |
| Maintaining rats on diets containing 0.015% capsaicin for eight weeks | Rat erythrocyte membranes | ESR; FA with DPH | Increase the fluidity | [ |
| Maintaining rats on diets containing 3.0% chili pepper or 0.01% capsaicin for eight weeks | Rat intestinal brush-border membranes | FP with DPH | Increase the fluidity | [ |
| Hyperforin | Guinea pig crude brain membranes | FA with DPH and TMA-DPH | Increase the fluidity of the hydrocarbon cores | [ |
| Hyperforin | Guinea pig crude brain membranes | FA with DPH and TMA-DPH | Decrease the fluidity of the hydrophilic regions | [ |
| Oral administration of St. John’s wort extract or hyperforin to murine | Murine brain neuronal membranes | FA with DPH and TMA-DPH | Decrease the fluidity | [ |
| Hypericin | DMPC liposomes | Microspectrofluorimetry | Decrease the fluidity | [ |
| Diallyl trisulfide; Diallyl disulfide | Tumor cell mimetic membranes; Platelet mimetic membranes | FP with DPH, TMA-DPH, 2-AS, 6-AS, 9-AS, 12-AS and 16-AP | Decrease the fluidity by preferentially acting on the hydrocarbon cores | [ |
| Diallyl trisulfide; Diallyl disulfide; Diallyl monosulfide | Candida cell mimetic membranes containing ergosterol | FP with DPH, TMA-DPH, 2-AS, 6-AS, 9-AS, 12-AS and 16-AP | Decrease the fluidity | [ |
| Ajoene | Phospholipid/cholesterol unilamellar vesicles | ESR | Increase the fluidity of the hydrocarbon chains | [ |
| Ajoene | Platelet plasma membranes; Artificial lipid membranes | ESR | Decrease the microviscosity | [ |
| Tetrahydroharman | Platelet mimetic membranes | FP with PNA and ANS | Increase the fluidity at antiplatelet concentrations | [ |
| Tetrahydroharman; Tetrahydronorharman | DPPC liposomes | FP with PNA and ANS | Increase the fluidity at high micromolar concentrations | [ |
| Tetrahydroharman | POPC/cholesterol liposomes | FP with PNA, ANS, DPH and TMA-DPH | Decrease the fluidity at low nanomolar concentrations Increase the fluidity at high micromolar concentrations | [ |
| Morphine | Rat erythrocyte membranes | Fourier transformed infrared spectroscopy; Fluorescence depolarization | Decrease the fluidity | [ |
| Morphine; Codeine | DPPC unilamellar vesicles | DSC; EPR | Decrease the mobility of the polar head groups | [ |
| Oral administration of piperine (5–20 mg/kg body weight) to rats for 5–15 min | Rat intestinal brush-border membranes | Fluorospectroscopy with pyrene | Increase the fluidity | [ |
| Piperine (2–50 μM) | Brush-border membrane vesicles from rat jejunum | Fluorospectroscopy with pyrene | Increase the fluidity | [ |
| Maintaining rats on diets containing 0.02% piperine for eight weeks | Rat intestinal brush-border membranes | FP with DPH | Increase the fluidity | [ |
| Aloin; Emodin | DMPC unilamellar vesicles; DMPG unilamellar vesicles | DSC; ESR | Perturb the membrane property and structure | [ |
| Ginsenoside Rb2; Rc; Rd; Re; Rf; Rg1; Rg2; Rh2 | HeLa cell membranes | Two-photon fluorescence microscopy; Generalized polarization imaging | Increase the fluidity | [ |
| Oral administration of ginsenoside Re (5–20 mg/kg body weight) to rats for seven days | Rat brain mitochondrial membranes | FP with DPH | Increase the fluidity | [ |
| Ginsenoside Rg3 (20 μM) | Human fibroblast carcinoma cell membranes | FA with DPH and TMA-DPH | Decrease the fluidity | [ |
| Oleanolic acid; Ursolic acid | DPPC liposomes | FP with DPH | Increase the fluidity in crystalline state Decrease the fluidity in liquid-crystalline state | [ |
| Curcumin (100–150 μM) | Human erythrocyte membranes | ESR | Increase the fluidity | [ |
| Maintaining experimental hypercholesterolemic rats on diets containing 0.2% curcumin for eight weeks | Rat erythrocyte membranes | ESR; FA with DPH | Increase the fluidity | [ |
| Curcumin | DOPC unilamellar vesicles | X-ray diffraction | Thin the lipid bilayer membranes and weaken their elasticity | [ |